This content is from: United States

Controversial inversions driven by lack of US tax reform

Inversion deals between companies such as Medtronic and Covidien, and failed attempts such as Pfizer’s desired takeover of AstraZeneca, have brought inversion transactions to the forefront of global tax issues. While the US government argues that inversion deals are anti-competitive, many taxpayers feel they are faced with an unappealing US tax system and have no choice but to look elsewhere.

To access our market-driven intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an ITR subscriber? Log in here

Instant access to all of our content. Membership Options | 30 Day Trial